Thomas A Burke1, Tami Wisniewski, Frank R Ernst. 1. Global Outcomes Research, Oncology, Global Human Health, Merck & Co., Inc, One Merck Drive, WS2E-76, Whitehouse Station, NJ 08889, USA. thomas_burke2@merck.com
Abstract
PURPOSE: Chemotherapy-induced nausea and vomiting (CINV), common adverse events of chemotherapy, may be associated with considerable healthcare resource utilization. This study was conducted to describe CINV-associated healthcare visits and costs following a first cycle of highly or moderately emetogenic chemotherapy (HEC or MEC). METHODS: This retrospective cohort study used the Premier Perspective™ Database to identify adult patients who received their first HEC or MEC and at least one antiemetic agent from 2003 to 2007 at US hospital-based outpatient facilities. Hospital visits with a CINV-related ICD-9 diagnosis were included from the chemotherapy administration date to 30 days later or 1 day before the second chemotherapy, whichever was first. CINV costs were hospital-reported costs. RESULTS: Of 19,139 patients (HEC, 16%; MEC, 84%), mean (SD) age was 59 (14) years; 59% were female; 66% were white. CINV prophylaxis included 5-HT₃ antagonists (85%), dexamethasone (76%), and NK-1 antagonists (2%). Overall, 13.8% of patients had a CINV-associated visit (HEC, 18%; MEC, 13%): 0.2% for acute CINV (day of chemotherapy, excluding chemotherapy administration visit) and 13.7% for delayed CINV. CINV-associated visits included inpatient (IP, 64%), outpatient (OP, 26%), and emergency room (ER, 10%) visits. Mean (SD) costs of CINV visits were $5,299 ($6,639); for IP, $7,448 ($7,271); OP, $1,494 ($2,172); and ER, $918 ($1,071). Mean per-patient CINV-associated costs across all patients were $731 ($3,069). Sensitivity analysis excluding visits where CINV was a secondary diagnosis code resulted in a CINV incidence of 4.4%, a mean CINV visit cost of $4,043, and a mean per-patient CINV-associated cost across all patients of $176. CONCLUSIONS: CINV visits in the first HEC or MEC cycle were common and costly, especially inpatient hospitalizations in the delayed phase. Strategies to reduce CINV in the delayed phase could reduce healthcare utilization and costs.
PURPOSE: Chemotherapy-induced nausea and vomiting (CINV), common adverse events of chemotherapy, may be associated with considerable healthcare resource utilization. This study was conducted to describe CINV-associated healthcare visits and costs following a first cycle of highly or moderately emetogenic chemotherapy (HEC or MEC). METHODS: This retrospective cohort study used the Premier Perspective™ Database to identify adult patients who received their first HEC or MEC and at least one antiemetic agent from 2003 to 2007 at US hospital-based outpatient facilities. Hospital visits with a CINV-related ICD-9 diagnosis were included from the chemotherapy administration date to 30 days later or 1 day before the second chemotherapy, whichever was first. CINV costs were hospital-reported costs. RESULTS: Of 19,139 patients (HEC, 16%; MEC, 84%), mean (SD) age was 59 (14) years; 59% were female; 66% were white. CINV prophylaxis included 5-HT₃ antagonists (85%), dexamethasone (76%), and NK-1 antagonists (2%). Overall, 13.8% of patients had a CINV-associated visit (HEC, 18%; MEC, 13%): 0.2% for acute CINV (day of chemotherapy, excluding chemotherapy administration visit) and 13.7% for delayed CINV. CINV-associated visits included inpatient (IP, 64%), outpatient (OP, 26%), and emergency room (ER, 10%) visits. Mean (SD) costs of CINV visits were $5,299 ($6,639); for IP, $7,448 ($7,271); OP, $1,494 ($2,172); and ER, $918 ($1,071). Mean per-patientCINV-associated costs across all patients were $731 ($3,069). Sensitivity analysis excluding visits where CINV was a secondary diagnosis code resulted in a CINV incidence of 4.4%, a mean CINV visit cost of $4,043, and a mean per-patientCINV-associated cost across all patients of $176. CONCLUSIONS:CINV visits in the first HEC or MEC cycle were common and costly, especially inpatient hospitalizations in the delayed phase. Strategies to reduce CINV in the delayed phase could reduce healthcare utilization and costs.
Authors: G R Morrow; J A Roscoe; J T Hickok; R M Stern; H I Pierce; D B King; T K Banerjee; P Weiden Journal: Oncology (Williston Park) Date: 1998-03 Impact factor: 2.990
Authors: Mark G Kris; Paul J Hesketh; Mark R Somerfield; Petra Feyer; Rebecca Clark-Snow; James M Koeller; Gary R Morrow; Lawrence W Chinnery; Maurice J Chesney; Richard J Gralla; Steven M Grunberg Journal: J Clin Oncol Date: 2006-05-22 Impact factor: 44.544
Authors: A Molassiotis; P Fernández-Ortega; D Pud; G Ozden; J A Scott; V Panteli; A Margulies; M Browall; M Magri; S Selvekerova; E Madsen; L Milovics; I Bruyns; G Gudmundsdottir; S Hummerston; A M-A Ahmad; N Platin; N Kearney; E Patiraki Journal: Ann Oncol Date: 2005-02-02 Impact factor: 32.976
Authors: Mark G Weiner; Alice Livshits; Carol Carozzoni; Erin McMenamin; Gene Gibson; Alison W Loren; Sean Hennessy Journal: AMIA Annu Symp Proc Date: 2003
Authors: A Molassiotis; M P Saunders; J Valle; G Wilson; P Lorigan; A Wardley; E Levine; R Cowan; J Loncaster; C Rittenberg Journal: Support Care Cancer Date: 2007-10-10 Impact factor: 3.603
Authors: Ilene H Zuckerman; Amy J Davidoff; Mujde Z Erten; Bruce Stuart; Thomas Shaffer; J Samantha Dougherty; Candice Yong Journal: Support Care Cancer Date: 2014-08 Impact factor: 3.603
Authors: Hoon-Kyo Kim; RueyKuen Hsieh; Alexandre Chan; Shiying Yu; Baohui Han; Yunong Gao; Ana Baños; Xiaoyan Ying; Thomas A Burke; Dorothy M K Keefe Journal: Support Care Cancer Date: 2014-08-21 Impact factor: 3.603
Authors: Rudolph M Navari; Kathryn J Ruddy; Thomas W LeBlanc; Ryan Nipp; Rebecca Clark-Snow; Lee Schwartzberg; Gary Binder; William L Bailey; Ravi Potluri; Luke M Schmerold; Eros Papademetriou; Eric J Roeland Journal: Oncologist Date: 2020-12-21
Authors: Tiffany K Weidner; John T Kidwell; David A Etzioni; Lindsey R Sangaralingham; Holly K Van Houten; Dennis Asante; Molly Moore Jeffery; Nilay Shah; Nabil Wasif Journal: J Gastrointest Surg Date: 2018-02-12 Impact factor: 3.452
Authors: Devon K Check; Katherine E Reeder-Hayes; Ethan M Basch; Leah L Zullig; Morris Weinberger; Stacie B Dusetzina Journal: Breast Cancer Res Treat Date: 2016-03-11 Impact factor: 4.872
Authors: Alan Carlotto; Virginia L Hogsett; Elyse M Maiorini; Janet G Razulis; Stephen T Sonis Journal: Pharmacoeconomics Date: 2013-09 Impact factor: 4.981